Entresto access in Egypt: the EDA named-patient pathway

Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.

Quick orientation

Entresto (sacubitril/valsartan) is the first member of the angiotensin receptor neprilysin inhibitor (ARNI) class. It is FDA-approved to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with chronic heart failure with reduced ejection fraction (HFrEF), with a 2021 label expansion to chronic heart failure across a broader range of ejection fractions, and a pediatric indication from October 2019 for patients one year of age and older with symptomatic heart failure due to systemic left ventricular dysfunction. In Egypt, Entresto is registered with the Egyptian Drug Authority (EDA) and available through standard distribution channels, yet specific patient cases still drive personal-importation demand: branded continuity, the 97/103 mg target-dose strength availability in secondary cities, and pediatric heart failure cases where weight-based dosing requires titration through multiple strengths. Reserved for you.

Why patients in Egypt need Entresto via NPP

Egypt is the most populous country in MENA and carries a significant chronic heart failure population, with the Magdi Yacoub Heart Foundation as the leading cardiovascular surgical and pediatric cardiology centre in the country. Entresto is registered with EDA and available through Novartis's local affiliate, which places this drug in the country module's first structural access gap rather than its third: registered, but the specific patient case may still need named-patient routing for one of three real-world reasons.

First, branded continuity. A patient initiated on US-manufactured Entresto at a Cleveland Clinic, Mayo Clinic, or other US cardiology centre and returning to Egypt may request continuity on the same product rather than rotation to a regionally distributed lot or to an Indian-licensed brand. Second, target-dose strength stocking gaps. EDA registration does not guarantee that every pharmacy carries every strength, and patients fully titrated to the 97/103 mg target maintenance dose in Cairo, Alexandria, or upper Egypt may find consistent supply of 49/51 mg but inconsistent stocking of 97/103 mg. Third, pediatric heart failure cases. The October 2019 pediatric indication is weight-based starting at lower mg/kg and titrating upward, and clinicians at the Magdi Yacoub Heart Foundation, Children's Cancer Hospital Egypt 57357 (for cardiotoxicity-related heart failure), and the pediatric cardiology services at Kasr Al Ainy and Ain Shams may select Entresto for pediatric patients with symptomatic systemic LV dysfunction and need reliable strength access across the titration arc. None of these scenarios involves off-label use. Each is supported by the FDA-approved label and the EMA centralised approval, simply routed through the EDA personal-importation corridor where local supply does not match the prescription.

The EDA named-patient pathway for Entresto

The Egyptian Drug Authority (EDA) was created by Law No. 151 of 2019, issued 25 August 2019 in the Official Gazette No. 34 bis (A), with executive regulations issued by Prime Minister Decision No. 777 of 2020 on 29 March 2020. EDA permits the importation of medicines for a specific patient under defined conditions, including where the available quantity of an equivalent registered product cannot meet the patient's clinical need or where the specific manufacturer continuity matters. The application is filed through the dispensing institution's import pharmacy: a private specialty hospital, a university hospital import desk, or a licensed specialty importer acting on the patient's behalf.

For Entresto specifically, the clinical justification angle in the EDA application anchors on one of three patterns. For an adult HFrEF patient titrated to a specific Novartis-manufactured lot, the letter documents the heart failure diagnosis (HFrEF with LVEF below 40 percent, or broader chronic heart failure under the 2021 expanded indication), prior ACE inhibitor or ARB therapy and reason for transition (with the 36-hour washout from ACE inhibitor recorded), the current titration step (24/26 mg twice daily, 49/51 mg twice daily, or 97/103 mg twice daily target maintenance), and the rationale for continuity on the US-manufactured Novartis product. For a pediatric heart failure case, the letter documents the underlying systemic LV dysfunction (cardiomyopathy aetiology, post-cardiotoxicity, post-cardiac surgery), the weight-based dosing plan per the FDA pediatric label table, and the dispensing facility's pediatric cardiology infrastructure. For a stocking-gap case, the letter documents the patient's titrated maintenance dose, the timeline on therapy, and the local pharmacy supply chronology that justifies the EDA application.

A complete application includes the clinical justification letter on hospital letterhead with the physician's stamp, the prescription specifying brand name (Entresto), generic name (sacubitril/valsartan), strength (24/26 mg, 49/51 mg, or 97/103 mg), dosage form (film-coated tablet), and quantity required (a three-month supply is standard). The package also requires a copy of the patient national ID or passport, the treating physician's Egyptian Medical Syndicate (EMS) membership number and Ministry of Health licence reference, full product details including manufacturer (Novartis Pharmaceuticals Corporation, US), country of origin, FDA approval reference (July 2015 initial approval, October 2019 pediatric, February 2021 expanded chronic HF indication), shelf life (typically 36 months from manufacture in sealed bottle or blister), the destination dispensing facility licence, and a chain-of-custody plan. Entresto is an ambient-temperature small molecule, which simplifies the customs and shipping documentation considerably versus refrigerated biologics. Routine EDA personal-import authorisations for well-documented cardiology cases are typically processed in a 3 to 6 week window, though this range varies by case complexity.

Where Entresto gets dispensed in Egypt

Entresto is an oral small-molecule tablet with no cold-chain requirement, so the dispensing facility list extends across the full Egyptian specialty hospital network without the storage constraints that narrow refrigerated biologic dispensing. Centres routinely engaged in cardiology and pediatric cardiology named-patient cases include the Magdi Yacoub Heart Foundation as the leading cardiovascular and pediatric cardiology centre, As-Salam International Hospital (the first hospital in the Middle East and 19th worldwide to earn JCI Clinical Care Certification for Acute Myocardial Infarction), Cairo University Hospitals (Kasr Al Ainy) with its cardiology, internal medicine, and pediatric services, Ain Shams University Hospitals with strong cardiology and pediatric programs, Dar Al Fouad Hospital (Alameda Healthcare Group, JCI-accredited, Cleveland Clinic cooperation since 1999), and the Cleopatra Hospitals Group across multiple Cairo facilities.

For Children's Cancer Hospital Egypt 57357 patients who develop chemotherapy-induced cardiomyopathy (a recognised long-term complication tracked by the hospital's Personalized Medication Management Unit), Entresto pediatric coordination flows through 57357's institutional import workflow with the cardiology consultant signing the clinical justification. For a regional patient outside Cairo, Giza, or Alexandria, the standard route is co-management with one of these centres or routing through a Cairo-based licensed specialty importer that handles the EDA filing, customs clearance, and final delivery to a licensed dispensing facility.

Real cost picture for Entresto in Egypt

Reserve Meds quotes patients in USD and accepts USD wire transfers. US wholesale acquisition cost (WAC) for Entresto is approximately USD 12.50 per day per published payer references, equating to roughly USD 4,500 per year at WAC across the three strengths. Cash-pay retail pricing in the United States ranges from approximately USD 600 to 700 per 30-day supply without insurance. The EGP has lost more than 70 percent of its value against the US dollar since early 2022, with the USD/EGP rate near 52 to 53 in May 2026; quoting in USD insulates the patient from intra-case currency drift.

The all-in delivered-to-Egypt cost includes the US drug acquisition, ambient-temperature international logistics from a US specialty distributor to Cairo International Airport (cheaper than the 2 to 8 degree Celsius cold-chain biologics in the Reserve Meds matrix, typically USD 400 to 800 per shipment), regulatory documentation handling fees on the Egyptian side, and the Reserve Meds coordination fee itemised on the firm quote. Three- and six-month supply windows reduce per-month logistics overhead and align with cardiology follow-up cadence. The January 2026 Medicare Part D Maximum Fair Price of USD 295 per 30-day supply applies only to US-domiciled Medicare beneficiaries and is not available for international named-patient procurement.

On the insurance side, Bupa Egypt, AXA Egypt, MetLife Egypt, Allianz Egypt, Misr Insurance, and other Egyptian carriers each assess specialty cardiology named-patient imports case by case. Universal Health Insurance Authority (UHIA) rollout under Law No. 2 of 2018 is governorate-phased through 2032 and does not generally cover specialty imports. Cash-pay remains the default posture; many Egyptian families reimburse themselves later if their private insurance covers a portion.

Typical timeline for Entresto in Egypt

From waitlist submission to first three-month supply in hand, the typical Entresto case in Egypt runs as follows. Reserve Meds confirms eligibility within 24 to 48 hours and sends a documentation kit to the treating cardiologist or pediatric cardiologist. The dispensing facility files the EDA personal-import application, which clears in 3 to 6 weeks for well-documented cases. In parallel, Reserve Meds aligns US-side specialty pharmacy sourcing. Ambient-temperature shipping shaves time off the cold-chain handoff, typically clearing in 4 to 7 business days for transit and customs at Cairo International Airport. The full cycle for an initial 90-day supply is typically 4 to 8 weeks. Re-supply on a chronic-therapy cadence aligns with quarterly cardiology check-ins (blood pressure, serum creatinine and eGFR, serum potassium, symptom assessment).

What your physician needs to provide

The clinical justification letter is the cornerstone of the EDA Entresto package. The letter, on the prescribing institution's letterhead and signed and stamped by an EMS-registered Egyptian physician with an active Ministry of Health licence, typically includes: diagnosis (chronic heart failure with reduced ejection fraction, broader chronic heart failure under the 2021 expanded indication, or pediatric symptomatic heart failure due to systemic LV dysfunction), severity markers including LVEF, NT-proBNP or BNP if available, NYHA functional class, and the relevant comorbidity context (ischaemic versus non-ischaemic aetiology, chronic kidney disease stage, diabetes status). The letter also documents the prior-therapy history (ACE inhibitor or ARB class and dose, beta-blocker, MRA, SGLT2 inhibitor, diuretic regimen), the 36-hour ACE inhibitor washout requirement before transitioning to Entresto, and the current titration step.

For pediatric cases, the letter documents the patient weight, the FDA pediatric label dosing reference, the underlying aetiology (cardiomyopathy, post-cardiotoxicity from CCHE 57357 oncology context, post-cardiac surgery), and the proposed weight-based titration plan. The letter also identifies the monitoring plan: baseline and periodic blood pressure, serum creatinine and eGFR, serum potassium, with more frequent monitoring during dose titration and in patients with chronic kidney disease, on potassium-sparing diuretics or potassium supplements, or with elderly status. The angioedema warning is acknowledged, with the FDA-noted higher incidence in Black patients flagged in the safety plan. The physician confirms their EMS membership and MoH licence are in active standing at the time of filing.

Common questions about Entresto in Egypt

Will Bupa Egypt, AXA Egypt, MetLife, Allianz, or Misr Insurance cover Entresto?

Each insurer assesses specialty cardiology named-patient imports case by case. Some plans reimburse a percentage when the drug treats a covered indication even if the specific product is not on a local formulary; many require pre-authorisation. We do not promise coverage. We supply the documentation set that allows your insurer to assess; the claim itself sits with you or your hospital.

If Entresto is registered with EDA, why route through personal importation?

The EDA personal-importation pathway addresses cases where the available quantity of an equivalent registered product cannot meet the patient's clinical need, or where specific manufacturer continuity matters. For a patient titrated to 97/103 mg twice daily who encounters supply gaps in a particular governorate, or for a patient initiated on US-manufactured Novartis Entresto at a US cardiology centre and requesting continuity, the personal-importation corridor provides the documented route.

Can a pediatric heart failure patient receive Entresto through this route?

Yes. The October 2019 FDA pediatric indication covers patients one year of age and older with symptomatic heart failure due to systemic left ventricular dysfunction. The Magdi Yacoub Heart Foundation, Kasr Al Ainy pediatric cardiology, Ain Shams pediatric cardiology, and CCHE 57357 (for post-cardiotoxicity cases) handle pediatric cardiology imports routinely. The clinical justification letter includes weight-based dosing per the FDA pediatric label table.

What is the safety profile and the ACE inhibitor washout?

The most frequent adverse events in the FDA-approved labeling are hypotension, hyperkalemia, cough, dizziness, and renal impairment. Angioedema occurred at 0.1 to 0.5 percent in clinical trials, with higher incidence in Black patients. Pregnancy is contraindicated. The 36-hour washout from any ACE inhibitor before starting Entresto is mandatory to reduce angioedema risk, and Entresto must not be combined with aliskiren in patients with diabetes or renal impairment.

What monitoring is required during therapy?

Baseline and periodic blood pressure, serum creatinine and eGFR, and serum potassium. More frequent monitoring during dose titration, in patients with chronic kidney disease, in patients on potassium-sparing diuretics or potassium supplements, and in elderly patients. Symptoms of angioedema (facial, lip, tongue, or airway swelling) require immediate discontinuation. Adverse events are reported to the Egyptian Pharmacovigilance Center (EPVC) per Egyptian pharmacovigilance obligations.

Why Entresto versus an ACE inhibitor or ARB?

PARADIGM-HF, published in NEJM in 2014, demonstrated that sacubitril/valsartan reduced the composite of cardiovascular death or heart failure hospitalization by 20 percent versus enalapril in HFrEF patients, and reduced all-cause mortality by 16 percent. Major guidelines (ACC/AHA/HFSA, ESC) now position ARNI as a Class I recommendation for symptomatic HFrEF. The clinical decision rests with the treating cardiologist.

Where Reserve Meds fits in Entresto cases

Reserve Meds is a US-based concierge coordinator. We do not replace the treating cardiologist or pediatric cardiologist, do not replace EDA, do not replace the Egyptian dispensing pharmacy, and do not act as an importer of record in Egypt. What we do is orchestrate US-side specialty pharmacy sourcing of Novartis-manufactured Entresto with DSCSA chain-of-custody documentation, prepare the regulatory documentation kit the treating physician needs for the EDA filing, coordinate the ambient-temperature international logistics to Cairo International Airport, and run a single named coordinator throughout your case in both English and Arabic. The local EDA filing, customs clearance, and final dispensing all remain with the licensed Egyptian dispensing facility. No prior Reserve Meds case experience with Entresto specifically at the time of this page; standard NPP coordination applies, and the chronic heart failure cadence aligns naturally with quarterly cardiology re-supply windows.

Next step

If the cardiologist or pediatric cardiologist has recommended Entresto and the Egyptian pharmacy supply, target-dose strength, or branded continuity does not match the prescription, the waitlist is the first step. We confirm eligibility within 24 to 48 hours and send the physician documentation kit, with Arabic-language patient summaries where the family requests them.

Reserved for you.

---

This guide is informational, not medical or legal advice. The EDA personal-importation framework requires a licensed Egyptian physician's clinical judgment; Reserve Meds is the coordinator, not the prescriber.